The Global Alliance for the Elimination of Leprosy (GAEL) was created by World Health Organization (WHO) in 1999 to ensure that a common strategy of leprosy elimination effort was adopted, intensively implemented and effectively monitored.
GAEL is a partnership dedicated to ensuring that all leprosy patients, wherever they may live, and however poor, have free and equal access to the most modern treatment available. The Multidrug therapy (MDT), donated by Novartis, has been made available free of charge to all endemic countries through WHO, and financial support has been provided by the Nippon and Sasakawa Foundations. MDT provides a simple yet highly effective cure for all types of leprosy in just six to twelve months.
The goal of GAEL is to eliminate leprosy as a public health problem from every country by the year 2005 and to detect and cure all the remaining leprosy cases (currently estimated at over 2.5 million). At its creation, GAEL included WHO, governments of endemic countries, the International Federation of Anti-Leprosy Associations, NGOs, DANIDA, the World Bank, the Nippon Foundation and the Sasakawa Memorial Health Foundation.